“Endoscopic ultrasound-guided tissue acquisition [EUS-TA] is the current standard-of-care for the diagnosis of pancreatic solid lesions,” stated Dr Serena Stigliano (University of Rome, Italy). “However, EUS sampling is associated with a risk of non-diagnostic or inconclusive results. Its negative predictive value is only about 70–80%.”
The current, multicentre study investigated the accuracy of FCM in predicting the diagnosis of EUS-TA samples of pancreatic solid lesions and its agreement with the final histological diagnosis. “FCM is an optical imaging technique to provide digital microscopical images of fresh tissue in real-time,” clarified Dr Stigliano. Included were 80 participants with focal pancreatic solid lesions. After the samples were obtained, they were evaluated by FCM (VivaScope) and categorised as ‘inadequate’ or ‘adequate’. “The ‘adequate’ samples were further classified as benign, suspicious, or malignant. Subsequently, the samples underwent the standard histological evaluation.
A 22-gauge needle was used with 66.3% of the participants, and a 25-gauge needle with 32.5% of participants. Dr Stigliano said that 96.3% of the samples were categorised as ‘adequate’. The sensitivity of VivaScope was 97.3%, the specificity was 80%, and the overall accuracy was 96.3%. Furthermore, the concordance between the VivaScope diagnosis and the final histological diagnosis was moderate (kappa Cohen’s coefficient 0.58). There was no association between the type and size of needles, or EUS technique with diagnostic sample obtainment.
Thus, FCM can quickly deliver information about sample adequacy and diagnosis of EUS-TA with high accuracy. “It offers the opportunity of creating a digital image and a ‘distant diagnosis’ to be used for remote consulting,” Dr Stigliano concluded.
- Stigliano S, et al. Digital confocal microscopy for real-time diagnosis of pancreatic solid lesion: a multicentre study. LB17, UEG Week 2024, 12–15 October, Vienna, Austria.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« New insights into perianal fistulising CD pathogenesis may lead to new therapeutics Next Article
Upadacitinib associated with normalisation of HRQoL in UC »
« New insights into perianal fistulising CD pathogenesis may lead to new therapeutics Next Article
Upadacitinib associated with normalisation of HRQoL in UC »
Table of Contents: UEGW 2024
Featured articles
Tamuzimod delivers promising long-term data in ulcerative colitis
CULTIVATE: Good signal for etrasimod in Crohn’s disease
Online First
Upadacitinib associated with normalisation of HRQoL in UC
Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA
New insights into perianal fistulising CD pathogenesis may lead to new therapeutics
TL1A inhibitor tulisokibart shows potential in ulcerative colitis
An accelerated treatment approach may save lives in pancreatic walled-off necrosis
Encouraging results for L-carnitine in non-alcoholic fatty liver disease
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Tamuzimod delivers promising long-term data in ulcerative colitis
Cendakimab meets primary endpoints in eosinophilic oesophagitis
How useful is colonoscopy for constipation in young women?
Guar gum alleviates IBS-related constipation in randomised-controlled trial
CULTIVATE: Good signal for etrasimod in Crohn’s disease
Meaningful corticosteroid-sparing effect of mirikizumab in UC
Is FMT a viable option to treat primary C. difficile infections?
Extending ustekinumab dosing interval does not influence drug survival in IBD
TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?
Related Articles
February 13, 2021
Details released for CLEAR study on advanced renal cell carcinoma
November 26, 2019
Novel mode of action for kidney cancer treatment
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com